interactive portfolio al3
TRANSCRIPT
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
Creative problem solver and strategic thinker always striving to keep the clients’ priority, first priority
Strong conceptual thinker that strives to meet the clients’ strategic goals whether on a single project or across an entire scope of work
Highly motivated and always looking to solve the next challenge
Adaptive design style to create what is most desirable and applicable to each project
Can take a project from concept through to finished deliverable
Work hands-on or with a team to achieve that goal depending on the scope of the work
Management of team members and outside vendors
Extensive agency experience predominantly in the pharmaceutical and healthcare communications field. Many of the skills used in developing, designing and completing projects for this industry can be applied readily to other fields of focus
Projects I have worked on range from print, digital (tablet), video, convention materials, e-mail, banners and web page design
▶Contact
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
Looking for that next challenge. I want to mix my creative force with an organization that inspires, believes, and supports the creative spirit. Searching for that environment that fosters success and breeds achievement. Looking to flex my creative muscle into the digital space where I can bring my design skills to the next level and communicate to a much larger audience.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
Proficient in:
Adobe Creative Suite — InDesign — Illustrator — Photoshop
Quark Xpress
Powerpoint
Adobe Acrobat
Knowledge of:
Adobe Digital Publishing Suite
Fireworks
Dreamweaver
Traditional skills:
Marker and paper comps
Storyboards
Illustration
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
Career highlights; Extensive pharmaceutical communications agency expertise, launch of new product extensions, thrives in fast paced environments, integration of tablet based digital sales platforms, supervise, manage, and mentor junior team members, interns, developers, freelancers, and other vendors, participant on many new business pitch teams, respected team member, regularly recruited by other teams to participate in conceptual brainstorming, viewed as a voice of reason with a get it done right the first time approach.
RX Club award winner 2002-2007, and 2010. Art Directors Club of NJ 2004 Gold Award.
Proficient in the use of Adobe Creative Suite (Indesign, Illustrator, and Photoshop), Adobe Acrobat, Quark Xpress, MS Powerpoint and Word.
Working knowledge of Fireworks, Dreamweaver and Adobe Digital Publishing
Traditional Skills include Marker and paper comps, storyboards and illustration
Work Experience:2/2012- Present Freelance Graphic Design Professional8/2006- 2/2012 Publicis LifeBrands/Medicus1997-8/2006 Adient/Commonhealth1994-1997 Miller Advertising
At the intersection of focused
thinking and creativity...
Alan D. Lessner
...exists that rare combination of design and business acumen
39 Beverly Hill Rd. Clifton, NJ. 07012 C. 201-280-4560 H. 973-458-0399 email: [email protected] Website: http://www.alanlessner.weebly.com/ Linked In profile: http://www.linkedin.com/pub/alan-lessner/9/90a/1a7
Strategic thinking
Objectively focused
Participation in client- agency workshops
Strategic development of the brand
Tactical planning
Client interaction
Help shape short and long-term brand strategies
Understands the science behind the brand, class and competing brands
Manage multiple projects within respective budgets, deadlines
and organizational procedures
Creative professional
History of successful advertising, branding, and design
Creative problem solving abilities
Conceptual aptitude
Development of compelling creative materials
Take projects from concept to completion
Conceptual development of the brand
Presentation of creative concepts
Immersed in brand identity
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
Rx Club 2002 Silver Award
Rx Club 2003-2007 and 2010 Award of Excellence
2004 Gold Award from Art Directors Club of NJ
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
For your patients with moderate UC…
Rapid relief is just the beginning
800DELAYED-RELEASE TABLETS
Brand: AsacolChosen concept for launch of Asacol HD campaign. Intended to communicate aspiration, hope and freedom for those patients living with a very intrusive disease state.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: Align/BifantisConcept based on active probiotic in Align. When IBS language was used Align branding could not be used, so Bifantis had to be promoted separately
Only Bifantis is proven to reduce all of the cardinal symptoms of IBS
Finally, a single solutionto restore GI function to normal
BIFANTISCLINICALLY PROVEN
Bifidobacterium infantis 35624
5B
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: MetamucilConcepts based on Metamucil’s fiber, psyllium and it’s MOA (Method of Action)
JUST A REMINDER
OF WHAT METAMUCIL REMOVES
Patients still don’t think fiber can offer more than motility
Only psyllium, the fiber found in Metamucil®, forms a thick gel that•traps and removes bile acids•helps lower cholesterol1
* Diets low in saturated fat and cholesterol that include 7 grams of soluble fiber per day from psyllium husk may reduce the risk of heart disease by lowering cholesterol. One serving of Metamucil psyllium powder or capsules has at least 2.1 grams of this soluble fiber. Use as directed.
The notion that fiber is fiber–doesn’t hold water
See why
†This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
isn’t your ordinary fiber
Recommend Metamucil—the fiber that does more for your patients
Unlike other leading brands, Metamucil contains psyllium, which retains water
and because psyllium can absorb water, it forms a gel and ✓ softens the stool ✓ increases stool volume✓ allows for faster, easier movement
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: PrilosecConcept based on continuous relief with focus on working at night.
24H URHEARTBURN
RELIEF
Recommend Prilosec OTCto block frequent heartburn—even through the night
CONTINUOUS
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: VireadConcept(s) based on new messaging to enhance brand competitiveness. Sample concept
D3
how can more clinical data support your decisions?
In chrOnIc hepatItIs B…
Many advances have been made in our understanding of how to optimize patient management in chronic hepatitis B
• Care can now be individualized to best meet every patient’s needs
• It is more important than ever to consider the clinical data supporting every decision made in patient management
there are many dimensions to clinical data, and the length of time studied is important as well as the number of patients studied
• Only a long-term track record in a large patient population can show us what to expect with a chronic condition
• As time goes on, additional benefits of patient management may become apparent
• Reversing cirrhosis and halting the progression of fibrosis could ultimately be other key considerations in patient management
Having a wealth of clinical data including reversing cirrhosis and halting the progression of fibrosis would give long-term insights into
patient management
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: New Business/AtlasConcept based on overwhelming strength, helped win new business for intravenous antibiotic
doripenem
New
Introducing greater penem
potency
Take on a world of serious infections…
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: New Business/NuVigilConcept based on effects lasting over 12 hours helped win new business for excessive sleepiness
IntroducingWakefulness that lasts
beyond the workday.
New
nuvigilnuvigilarmodafinil C tabletsIV
TM
NuvigilWorks long enough to help hypersomnolent patients stay awake, alert and engaged at work and beyond.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
In the treatment of occasional digestive upsets
† Among gastroenterologists who recommended a brand of probiotic in a Wolters Kluwer 2009 survey.‡ When taken daily.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
** MONEY BACK GUARANTEE: We stand behind our product. If you are not satisfied with Align, simply return the UPC code from the Align package and your original sales receipt within 60 days of purchase for a full refund. Void in Maine. Visit AlignGI.com/Refund for details.
Extra value in every package—Over $40 in coupons for P&G products
RECOMMEND THAT PATIENTS AND COLLEAGUESSTART MONTH ONE WITH ALIGN TODAY
Only Align contains BIFANTIS®
(Bifidobacterium infantis 35624)
– a well-studied patented strain that helps protect against occasional digestive upsets
Satisfaction guaranteed or your patients’ money back**
• Restore natural digestive balance
• Build & maintain a healthy digestive system
• Protect against occasional digestive upsets
In just 28 days, Align® can naturally help*:
STARTING WITH MONTH ONEBALANCE
HELPPATIENTS ACHIEVEDIGESTIVE
†
Brand: AlignVisual synergy with the consumer agency campaign while making message relevant to health care professionals. This design was used for sell sheets, tear pads, and pharmacist focused messaging
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Recommend Metamucil— the fiber that does more for your patients
*
* Based on Wolters Kluwer fiber supplement survey.
All fibers can benefit patients seeking regularity, but psyllium has a distinct advantage…
No other leading fiber contains psyllium. The psyllium in Metamucil forms a gel for unmatched
benefits for patients with constipation:
• Softens the stool
• Increases stool volume
• Allows for faster, easier movement
Metamucil—The only leading fiber that
Brand: MetamucilGEL concept based on the brands MOA, was used for sell sheets, pharmacist focused communication, tear pads, patient focused materials, and e-mail alerts .
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
FOR YOUR PATIENTS WITH FREQUENT HEARTBURN, RECOMMEND PRILOSEC OTC,
SATISFACTION GUARANTEED.
†
‡of patients rated Prilosec OTC “good” to “excellent” in allowing a restful night
H 94% of patients were satisfied with how well Prilosec OTC works
H 90%
of patients had complete relief or only mild symptoms on the first day of treatment
H 81%
In separate studies of frequent heartburn patients:
H #1 Physician recommended for over 10 years
Brand: PrilosecChosen concept based on patient satisfaction. Used for an array of collateral materials. Worked with consumer campaign visual identity while having a physician focused message
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: AsacolCover of Asacol HD Core Visual Aid showing how winning concept was implemented. Sales force was enthused to detail this new product
Are your patients heading in the right direction?
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Rap
idS
ymp
tom
Imp
rove
men
t
Please see Selected Safety Information on adjoining page and accompanying full prescribing information.References: 1. Data on file, Procter & Gamble Pharmaceuticals, Inc. 2. Hanauer SB et al. Am J Gastroenterol. 2005;100:2478-2485.
Please see Selected Safety Information on adjoining page and accompanying full prescribing information.References: 1. Data on file, Procter & Gamble Pharmaceuticals, Inc. 2. Hanauer SB et al. Am J Gastroenterol. 2005;100:2478-2485.
NEWHelp patients reduce their UC symptoms
so their lives can be more predictable
76%79%
64%
74%
n=77/104n=70/110n=280/353n=279/365
%PatientsIm
prove
d
90
80
70
60
10
0
3 Weeks
6 Weeks
Improvement in Stool Frequency
ASCEND III1 ASCEND II1,2
Asacol HD 4.8 g/day in Patients With Moderately Active UC
ASCEND III1 ASCEND II1,2
%PatientsIm
prove
d
90
80
70
60
10
0
78%84%
75%79%
n=84/107n=82/110n=298/353n=283/365
3 Weeks
6 Weeks
Improvement in Rectal Bleeding
FOR INTERNAL TRAINING PURPOSES ONLY—NOT FOR USE IN PROMOTION
STEP 1.Introduce Asacol HD.
STEP 4.Show the benefit that rapidsymptom improvement canbring to the life of the patienttype being discussed. Use theimage of the patient engagedin activities to bring the storyto life. Reiterate that “rapidsymptom improvementenables UC patients toreconnect with more of theireveryday lives.”
NOTE:The blue and orange colors portray atrustable brand and introduce adifferentiating new product.• The blue color is a groundedcolor that represents years ofcommitment to UC by P&GP.Blue is also a soothing color thatrepresents symptom improvement.This color should be familiar tophysicians who have beenpromoted to in the past.
• The orange color is a distinct colorin the UC market. It draws attentionto the modifier HD, to distinguishbetween the 800 mg Asacol HDtablet and the 400 mg doses.Asacol tablet. Orange is a boldcolor that represents the new 800mg product while yellow representsthe heritage of the 400 mg product.Also, the "800 mg per tablet"information emphasizes that thisnew product is a high dose.
STEP 2.Establish a problem/need. Use thepatient image on the compass icon tocreate a relevant patient type-patientwith moderately active UC. Use thisstatement as a problem/need.
NOTE:On this page, the iconic rapid lines are thevisual representation of rapid symptomimprovement. This message can enableAsacol HD to win in market because it isrelevant and differentiating.• Rapid symptom improvement is relevant toboth patients and physicians. A key treatmentoutcome is to achieve rapid symptomimprovement so that patients can reconnectto their everyday lives.
• Rapid symptom improvement can helpestablish differentiation. You can reframe"convenience" to be the ability for patients toreengage in the activities and relationshipsthat are important to them. Rapid symptomimprovement in as few as 3 weeks can helppatients to this.
STEP 3.Deliver the message that Asacol HDdelivers rapid symptom improvementin as few as 3 weeks, for moderatelyactive UC.
Rectal Bleeding Improvement at 3 & 6 Weeks
Clinic visit at baseline, 3 & 6 weeks. Improvementdefined as > 1 point improvement in RB score frombaseline to time point.
Assessment Scoring0 = no blood seen1 = streaks of blood with stool less than half the time2 = obvious blood with stool most of the time3 = blood alone passed
Stool Frequency Improvement at 3 & 6 Weeks
Clinic visit at baseline, 3 & 6 weeks. Improvementdefined as > 1 point improvement in SF score frombaseline to time point.
Assessment Scoring0 = normal SF per day1 = 1-2 stools > normal per day2 = 3-4 stools > normal per day3 = 5 or more > normal per day
FOR INTERNAL TRAINING PURPOSES ONLY—NOT FOR USE IN PROMOTION
NEW
INTRODUCING THEASACOL®ANDASACOL® HD COMPASS CAMPAIGNThe launch of Asacol HD is an exciting time. We are striving to maintain and build on the trust of physiciansand patients that has been earned during the 17 years of familiarity with P&GP brands such as Asacol.
We took this opportunity to design a new look for the promotional materials for the UC franchise. We call it theCompass Campaign. The imagery should help you link the feature of rapid symptom improvement to the potentialbenefit to patients: Rapid symptom improvement can help enable UC patients to reconnect with their everyday life.
Compass: navigation tool that helps people to find their wayEven normal, everyday activities can present a challenge to people who are touched by UC.
The compass symbolizes the therapy, the powerful tool that physicians can prescribe for their patients to help them quickly find their wayto re-engage with more of the life they have been missing.
Person engaged in activity:what is possible when a patientgets rapid symptom improvementAsacol or Asacol HD has helpedthis patient with UC symptoms.The imagery is of the self-realizedpatient who has reached more ofhis or her goals.
Person standing on the compass:everyday patient type, navigatorof his or her reclaimed lifeThe patient type is someone whodoctors see in their practice—a real-lifeperson doing real-life things, not toolofty, not impossible. The patient ismale or female, a young adult, a parent,or an older person of 50 or 60. UCdoes not discriminate, and the Asacoland Asacol HD brands reach out to alladult sufferers.
The patient is surrounded by iconsthat represent the passions and theuntapped potential in this person’s life.The patient’s stance projects the brandoverall equity: confidence to reconnectUC patients with everyday possibilitiesThe patient is confident; he or shecould go anywhere; the world is nowopen. The patient is ready to reconnectwith at least one of the iconic passionsor potentials.
Compass Campaign + Data = A complete story individualized according to patient type
Brand: AsacolInternal trainer to help familiarize the sales force with the new visual identity and how to best detail using the new Asacol HD campaign. Front/back
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct MailMy liver. My fight. My VIREAD.
Indication and UsageVIREAD® (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B in adults.
The following points should be considered when initiating therapy with VIREAD for the treatment of HBV infection:
•This indication is based primarily on data from treatment of subjects who were nucleoside–treatment-naïve and a smaller number of subjects who had previously received lamivudine or adefovir dipivoxil. Subjects were adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease
•VIREAD was evaluated in a limited number of subjects with chronic hepatitis B and decompensated liver disease
•The numbers of subjects in clinical trials who had lamivudine- or adefovir-associated substitutions at baseline were too small to reach conclusions of efficacy
Important Safety InformationWARNINGS: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS•Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with
the use of nucleoside analogs, including VIREAD, in combination with other antiretrovirals
•Severe acute exacerbations of hepatitis have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted
For treatment-naïve adult patients with chronic hepatitis B…
REASONS TO FOCUS ON VIREAD FIRST LINE
Follow-up in trial design
Please see additional Important Safety Information for VIREAD on subsequent pages 12-13.
* Based on data provided by Wolters Kluwer Pharma Solutions, Source® Pharmaceutical Audit Suite, Source® Prescriber Payer, Retail and Mail Order, January 2010–April 2011.
#3Reason
Resistance
Reason
Viral suppression & S
loss
Reason
Robust patient fo
llow
-up
Reason
DosingViral suppression
& potential for S loss
#1Reason
Resistance
Reason
Viral suppression & S
loss
Reason
Robust patient fo
llow
-up
Reason
DosingRobust follow-up
in trial design
#2Reason
Resistance
Reason
Viral suppression & S
loss
Reason
Robust patient fo
llow
-up
Reason
DosingResistance
According to
prescription data,
prescribed
oral antiviral
for chronic hepatitis B
in adults1*
Important Safety Inform
ationResistance
Viral suppression & S loss
Brand: VireadVisual Aid tightly focused on 3 strategic reasons to prescribe Viread. A brand which has a “Black Box Warning” so the safety messaging needed to have the same visual prominence as the promotional message.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: VireadSales tool designed as an objection handler, focusing on one key message while blunting a competitors perceived message.
Indication and UsageVIREAD® (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B in adults.
The following points should be considered when initiating therapy with VIREAD for the treatment of HBV infection:
•This indication is based primarily on data from treatment of subjects who were nucleoside–treatment-naïve and a smaller number of subjects who had previously received lamivudine or adefovir dipivoxil. Subjects were adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease
•VIREAD was evaluated in a limited number of subjects with chronic hepatitis B and decompensated liver disease
•The numbers of subjects in clinical trials who had lamivudine- or adefovir-associated substitutions at baseline were too small to reach conclusions of efficacy
Important Safety InformationWARNINGS: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS•Lacticacidosisandseverehepatomegalywithsteatosis,includingfatalcases,havebeenreportedwiththeuseof
nucleosideanalogs,includingVIREAD,incombinationwithotherantiretrovirals
•SevereacuteexacerbationsofhepatitishavebeenreportedinHBV-infectedpatientswhohavediscontinuedanti-hepatitisBtherapy,includingVIREAD.Hepaticfunctionshouldbemonitoredcloselywithbothclinicalandlaboratoryfollow-upforatleastseveralmonthsinpatientswhodiscontinueanti-hepatitisBtherapy,includingVIREAD.Ifappropriate,resumptionofanti-hepatitisBtherapymaybewarranted
Please see additional Important Safety Information for VIREAD on page 5.Please see accompanying full Prescribing Information for VIREAD, including boxed WARNINGS.
© 2011 Gilead Sciences, Inc. All rights reserved. VP9627 6/11
References:1. VIREAD Prescribing Information, Foster City, CA: Gilead Sciences, Inc.; October 2010. 2. Study 102. Data on file, Gilead Sciences, Inc. 3. Study 103. Data on file, Gilead Sciences, Inc. 4. Data on file, Gilead Sciences, Inc. 5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol. 2009;50:227-242. 6. Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: Prevention of drug resistance. Clin Liver Dis. 2007; 11:869-892.
WarningsandPrecautionsPlease see additional Important Safety Information for VIREAD on front page, including boxed WARNING information about lactic acidosis, severe hepatomegaly with steatosis, and post treatment exacerbation of hepatitis. • Newonsetorworseningrenalimpairment: New onset or
worsening renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), have been reported with the use of VIREAD. Assess creatinine clearance (CrCl) before initiating treatment with VIREAD. Monitor CrCl and serum phosphorus in patients at risk, including those who have previously experienced renal events while receiving HEPSERA® (adefovir dipivoxil). Avoid administering VIREAD with concurrent or recent use of nephrotoxic drugs. Dosing interval adjustment of VIREAD and close monitoring of renal function are recommended in all patients with CrCl <50 mL/min
• Coadministrationwithotherproducts: — Do not use with other tenofovir-containing products
(eg, ATRIPLA® [efavirenz/emtricitabine/tenofovir disoproxil fumarate] and TRUVADA® [emtricitabine/tenofovir disoproxil fumarate])
— Do not administer in combination with HEPSERA
• PatientscoinfectedwithHIV-1andHBV:Due to the risk of development of HIV-1 resistance, VIREAD should only be used in HIV-1 and HBV coinfected patients as part of an appropriate antiretroviral combination regimen. HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with VIREAD
• Decreasesinbonemineraldensity:Decreases in bone mineral density (BMD) have been observed in HIV-infected patients. Consider monitoring BMD in patients with a history of pathologic fracture or who are at risk for osteopenia. The bone effects of VIREAD have not been studied in patients with chronic HBV infection. Cases of osteomalacia (associated with proximal renal tubulopathy and which may contribute to fractures) have been reported in association with the use of VIREAD
AdverseReactions• InHBV-infectedpatientswithcompensatedliverdisease:
Most common adverse reaction (all grades) was nausea (9%). Other treatment-emergent adverse reactions reported in >5% of patients treated with VIREAD included: abdominal pain, diarrhea, headache, dizziness, fatigue, nasopharyngitis, back pain, and skin rash
• InHBV-infectedpatientswithdecompensatedliverdisease:Most common adverse reactions (all grades) reported in ≥10% of patients treated with VIREAD were abdominal pain (22%), nausea (20%), insomnia (18%), pruritus (16%), vomiting (13%), dizziness (13%), and pyrexia (11%)
a Calculated using ideal (lean) body weight.b Generally once weekly assuming three hemodialysis sessions a week of approximately 4 hours’ duration. VIREAD should be administered following completion of dialysis.
• The pharmacokinetics of tenofovir have not been evaluated in non-hemodialysis patients with creatinine clearance <10 mL/min; therefore, no dosing recommendation is available for these patients
• No dose adjustment is necessary for patients with mild renal impairment (creatinine clearance 50-80 mL/min). Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in these patients
Recommended300mgdosinginterval
Every 7 days or after a total of approximately
12 hours of dialysisb
Every 24 hours
Every 48 hours
Every 72 to 96 hours
Creatinineclearance(mL/min)a
≥50 30-49 10-29Hemodialysispatients
DrugInteractions• Didanosine:Coadministration increases didanosine
concentrations. Use with caution and monitor for evidence of didanosine toxicity (eg, pancreatitis, neuropathy). Didanosine should be discontinued in patients who develop didanosine- associated adverse reactions. In adults weighing >60 kg, the didanosine dose should be reduced to 250 mg when it is coadministered with VIREAD. Data are not available to recommend a dose adjustment of didanosine for patients weighing <60 kg
• Atazanavir: Coadministration decreases atazanavir concentrations and increases tenofovir concentrations. Use atazanavir with VIREAD only with additional ritonavir; monitor for evidence of tenofovir toxicity
• Lopinavir/ritonavir:Coadministration increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity
DosageandAdministration• Recommended dose for the treatment of chronic hepatitis B:
300 mg once daily taken orally without regard to food. In the treatment of chronic hepatitis B, the optimal duration of treatment is unknown
• The dosing interval of VIREAD should be adjusted (using recommendations in the table below) and renal function closely monitored in patients with creatinine clearance <50 mL/min
Dosage Adjustment for Patients with Altered Creatinine Clearance
Please see accompanying full Prescribing Information for VIREAD, including boxed WARNINGS.
My liver. My fight. My VIREAD.
Strong against resistanceImportant Safety Information (continued)
5 6
In Studies 102 (HBeAg–) and 103 (HBeAg+), 641 adult patients with chronic hepatitis B (CHB) and compensated liver disease who were primarily nucleoside–treatment-naïve entered a 48-week, randomized, double-blind, active-controlled treatment period comparing VIREAD 300 mg to Hepsera® (adefovir dipivoxil) 10 mg, with a primary endpoint of complete response (HBV DNA <400 copies/mL + histological response*). 585 patients then rolled over with no interruption in treatment to open-label VIREAD for analysis through Week 144.1-3
*Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis score.1
VIREAD, HEPSERA, and TRUVADA are registered trademarks of Gilead Sciences, Inc. ATRIPLA is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: VireadNewsletter designed to coincide with Gilead National meeting. The content contains interviews, highlights, keynotes and imagery from the event. Its intent is to be informative yet fun and engaging. The sales force is the key audience
confidential: for internal gilead use only.
In This Issue:
• Driving Differentiation With Resistance
• Expanding Reach and Impact
• Opinion Leader Game Plan
Winners of First Top Honors Competition
At the Mid-Year Meeting, all winners demonstrated top knowledge of the data and a talent for putting it into practice in topnotch details.
Congratulations to the TSs who have proven
their competitive edge with some of the
strongest VIREAD HBV:ETV ratios in the country
leading up to the Mid-Year Meeting
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: RemodulinCore visual aid designed to work with new concept. Highlighting new data with new chart design updated color palate. Cover
• Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH
• Initiation of Remodulin must be performed in a setting with adequate personnel and equipment for physiological monitoring and emergency care
Please see full Indication and Important Safety Information on pages 2 and 3 and Full Prescribing Information in pocket.
Remodulin® (treprostinil) Injection is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise.
Remodulin: Flexibility to help meet patients’ needs1
It’s TIME for…
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: ClaritinJournal ad designed to work with existing campaign while announcing a new flavor for children’s Claritin. Also re purposed as direct mail.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: AsacolClient wished to migrate from traditional printed sales materials to tablet based selling. Design based on printed materials to work in the digital space. Developed layouts of each section and worked with developer to ensure message and creative integrity of new concept were kept.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: VireadDesign of this Digital Sales Aid was based on the printed version while incorporating many levels of navigation to make for a much more fluid presentation of the information. The design called for a very clinical look and feel.
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brands: Align/Metamucil/Prilosec OTCE-mail blasts designed to match other branded (printed) sales collateral to reach pharmacists as part of non-personal outreach through e-Pharm alerts. Designed to get the first priority of communication (free samples) to be above the fold line
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
SKYNET SKYNET
• • • • • • •
••••
•••
••••
•••
• • • • • • • • • • • • • • • • • • • • • •
••••••••••••••
• • • • • • •SKYNET
SKYNET SKYNET
• • • • • • •
••••
•••
••••
•••
• • • • • • • • • • • • • • • • • • • • • •
••••••••••••••
• • • • • • •SKYNET
SKYNET SKYNET
• • • • • • •
••••
•••
••••
•••
• • • • • • • • • • • • • • • • • • • • • •
••••••••••••••
• • • • • • •SKYNET
SKYNET SKYNET
• • • • • • •
••••
•••
••••
•••
• • • • • • • • • • • • • • • • • • • • • •
••••••••••••••
• • • • • • •SKYNET
SKYNET SKYNET
• • • • • • •
••••
•••
••••
•••
• • • • • • • • • • • • • • • • • • • • • •
••••••••••••••
• • • • • • •SKYNET
DELAYED-RELEASE TABLETS
®
Not just proven. Proven by you.
Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses). In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo,respectively, were headache (35% vs 36%), abdominal pain (18% vs 14%), and eructation (16% vs 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs 50%), rhinitis (42% vs 36%), and diarrhea (35% vs 50%).Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol.Please see accompanying full prescribing information.
Lialda is indicated for the induction of remission in patients with active, mild to moderate UC (the recommended dosage is two to four 1.2 g tablets qd with meal for 8 weeks).
Colazal is indicated for the treatment of mildly to moderately active UC (the indicated dosage is three 750 mg capsules tid for 8 weeks).
There are currently no head-to-head trials comparing the efficacy and safety of US Asacol with Colazal.
Not all 5-ASA studies have included proctitis patients
Pro
ctitis
Colazal is a registered trademark of Salix Pharmaceuticals, Inc.Lialda is a trademark of Shire LLC.
‡ Proctitis defined as less than 15 cm of active disease.§ Proctitis defined as less than 12 cm of active disease.
References: 1. Loftus EV et al. Gut. 2000;46:336-343. 2. Lichtenstein et al.Clin Gastroenterol Hepatol. 2007;5:95-102. 3. Kamm et al. Gastroenterology.2007;132:66-75. 4. Green JRB et al. Gastroenterology. 1998;114:15-22. 5. Pruitt R et al. Am J Gastroenterol. 2002;97:3078-3086. 6. Levine DS et al.Am J Gastroenterol. 2002;97:1398-1407.
Proctitis can be difficult to treat in UC patients…
Asacol Offers Proven Efficacy in ProctitisPlus 15 Years of Experience
Disease Extent in 5-ASA Studies
5-ASA Study Proctitis patients included?
Lialda™ (mesalamine) MATRX 12 No‡
Lialda MATRX 23 No‡
Colazal® (balsalazide disodium) Green et al4 No§
Colazal Pruitt et al5 No§
Colazal Levine et al6 Not reported§
EVIDENCE
EXPERIENCE
#Recommended by Allergists
#Recommended
by Allergists
#Recommended by Allergists
#
Re
commended
by Allergists
# Recommended by AllergistsRecommended by Allergists
# Recommended by AllergistsRecommended by Allergists
#Recommended by Allergists
Recommended by Allergists#
Recommended by Allergists
# #
Re
commended
by Allergists
Recommended by Allergists
#Recommended
by Allergists
##
Recommended by Allergists
#Recommended
by Allergists
#Recommended by Allergists
#Recommended
by Allergists
#Recommended by Allergists
#
Re
commended
by Allergists
# Recommended by AllergistsRecommended by Allergists
# Recommended by AllergistsRecommended by Allergists
#Recommended by Allergists
Recommended by Allergists#
Recommended by Allergists
# #
Re
commended
by Allergists
Recommended by Allergists
#Recommended
by Allergists
##
Recommended by Allergists
#Recommended
by Allergists
#Recommended by Allergists
#Recommended
by Allergists
#Recommended by Allergists
#
Re
commended
by Allergists
# Recommended by AllergistsRecommended by Allergists
# Recommended by AllergistsRecommended by Allergists
#Recommended by Allergists
Recommended by Allergists#
Recommended by Allergists
# #
Re
commended
by Allergists
Recommended by Allergists
#Recommended
by Allergists
##
Recommended by Allergists
#Recommended
by Allergists
#Recommended by Allergists
#Recommended
by Allergists
#Recommended by Allergists
#
Re
commended
by Allergists
# Recommended by AllergistsRecommended by Allergists
# Recommended by AllergistsRecommended by Allergists
#Recommended by Allergists
Recommended by Allergists#
Recommended by Allergists
# #
Re
commended
by Allergists
Recommended by Allergists
#Recommended
by Allergists
##
Recommended by Allergists
#Recommended
by Allergists
15thanniversary
NEW YORK XVIII
15thanniversary
15thanniversary
BLUE KNIGHTS
NEW YORK XVIII
BLUE KNIGHTS
NEW YORK XVIII
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: LevaquinMultiple wave direct mail projects. RX Club award winning series. Dimensional devices to simple yet engaging post card designs
Direct Mail
Direct Mail
Direct Mail
◀ ▶
Alan Lessner
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
Brand: VireadPatient starter kit with attached pill holder premium, multiple options presented to client
PILL BOX
7”1.25”
1.75”
3.75”3 boxes depth
◀ ▶
Alan Lessner
Pill box sits in well.
Coupon and Patient reminder card (Cling-Z) (3.5” x 5.25”)�t in pocket
Viread pill box
Contents of Kit
1.25”
1.75”
7”
9”
6”
Patient education
video
4.625”
1 month Free
Coupon
magnet under paperfor secure closure
Patient education brochure covers pill box
DVD held in place by foam button
Patient Starter Kit -Schematic
PILL BOX
7”1.25”
1.75”
3.75”3 boxes depth
Pill box sits in well.
Coupon and Patient reminder card (Cling-Z) (3.5” x 5.25”)�t in pocket
Viread pill box
PAPER OPTION with Magnet closure
1.25”
1.75”
7”
9”
6”
Patient education
video
4.625”
1 month Free
Coupon
magnet under paperfor secure closure
Patient education brochure covers pill box
DVD held in place by foam button
Kit closedshowing spine
Kit closedshowing where to lift
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
—Concepts
—Digital
—Logos
—Direct Mail
◀ ▶
Alan Lessner
Brand: P&G Digestive WellnessSample kits for healthcare professionals containing samples and sales materials for 3 brands Prilosec, Metamucil and Align, multiple options presented to client
Contact
Professional summary
Future career objectives
Skills
Resume
Achievements
Samples
201-280-4560
http://www.alanlessner.weebly.com/
My Linked In Profile
◀
Alan Lessner